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Abstract: Objectives: Transient B cell depletion with the monoclonal anti-CD20 antibody rituximab has shown favour-
able clinical responses in patients with rheumatoid arthritis (RA). Recently a characteristic regeneration pattern of B cell 
subpopulations has been reported. However, little is known about the impact of B-cell depletion on peripheral T cells in 
particular regulatory T cells. 
Materials and Methodology: 17 patients with RA having failed anti-TNF were treated with rituximab. Four colour stain-
ing was performed using CD19, CD3, CD4, CD8, CD16, CD56, CD25, HLA-DR, HLA-G and intracellular Foxp3 at five 
time points spanning up to 12 months after rituximab. In addition, quantification of the soluble form of the HLA class I 
molecule HLA-G by ELISA has been performed. 
Results: Peripheral B cell depletion lasted 6 to 9 months. The absolute number of CD3+, CD4+ and CD8+ lymphocytes 
showed no significant changes up to 1 year after B-cell depletion compared to before therapy. Only the relative frequency 
for CD3 and CD4 showed a significant increase (p < 0.05). In particular, CD4+CD25++ and Foxp3 positive regulatory T 
cells remained constant. The percentage of HLA-G positive cells in the CD4+ or CD8+ population did not change signifi-
cantly either. The amount of sHLA-G remained without significant changes. 
Conclusion: Absolute T cell counts showed no significant changes after rituximab compared to the time point before ther-
apy. In particular, the frequency of regulatory T cells with a CD4+CD25++ phenotype as well as positive Foxp3 expres-
sion were numerically stable. Additionally, HLA-G positive regulatory T cells and soluble levels of HLA-G showed no 
significant changes. 
INTRODUCTION 
  Rheumatoid arthritis (RA) represents a chronic inflam-
matory disease leading to progressive cartilage and joint de-
struction. RA is treated with DMARDs (disease modifying 
anti-rheumatic drugs) alone or in combination with glucocor-
ticoids and/or so called biologicals, e.g. TNFalpha-
antagonists. The introduction of TNFalpha blockers has 
revolutionized treatment of RA. Nevertheless, up to one third 
of by this means treated patients does not respond adequately 
[1]. Therefore there is still need for other treatment strategies 
like rituximab, a B-cell depleting anit-CD20 monoclonal 
antibody [2-4]. Within the last years growing evidence has 
emerged underlining the pathogenetical role of B lympho-
cytes in RA [5-9]. In several clinical trials B cell depletion 
with rituximab has been shown to be effective in treatment 
of RA and well tolerated by patients. Peripheral B cell deple-
tion lasts usually 6-9 months. Recently a characteristic re-
generation pattern of B cell subpopulations with a long last-
ing modulation of B cell subset composition has been re-
ported [10, 11]. 
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  Regulatory T (Treg) cells represent a distinct subset of 
lymphocytes. They are attributed to have a key function in 
limiting immune responses against infectious agents and in 
avoiding pathologic autoimmunity. Defects in Treg function 
are discussed to play an important role in the pathophysiol-
ogy of autoimmune diseases such as rheumatoid arthritis 
(RA) [12, 13]. 
  There are still different concepts in defining Treg [14-
17]. The best described Treg population is thought to be 
CD4+CD25++. In addition to this, Tregs have been defined 
by the expression of CD4 and the transcription factor Foxp3. 
Foxp3 seems to be characteristically expressed by Tregs and 
plays an important role in development of Tregs. Recently, a 
new subset of CD4 and CD8 positive T cells has been re-
ported, characterized by the constitutive expression of the 
immunotolerogenic molecule HLA-G [18]. Besides the 
membrane-bound isoforms, HLA-G can be secreted and is 
found at detectable levels in the peripheral blood. Both, 
membrane bound and soluble HLA-G levels have been 
linked to the pathogenesis of autoimmune diseases and pre-
vious data suggest a positive correlation between soluble 
HLA-G (sHLA-G) and disease activity in rheumatoid arthri-
tis patients [19]. 
  The role of Treg in RA is still not exactly defined [20-
22]. Tregs from synovial fluid showed increased expression 82    The Open Rheumatology Journal, 2008, Volume 2  Feuchtenberger et al. 
of activation markers like CTLA-4 (both surface and intra-
cellular), GITR and OX40, as well as Foxp3 transcripts [23]. 
  B cells have multiple effects on the T cell compartment. 
They directly interact with T cells during antigen presenta-
tion, produce cytokines and have specific functions for the 
organization of tertiary lymphoid structures like germinal 
center formation [24]. However, very little is known about 
the impact of B-cell depletion on peripheral T cell subpopu-
lations. Particularly regulatory T cells are important candi-
dates which may be indirectly influenced by rituximab 
treatment. In this study, four colour staining was performed 
using CD19, CD27, CD3, CD4, CD8, CD16, CD56, CD25, 
HLA-DR, HLA-G and intracellular Foxp3 to study the ef-
fects of B cell depletion mediated by rituximab on different 
subsets of T cells with particular interest in regulatory T 
cells. In addition, quantification of sHLA-G in sera of five 
patients has been performed. 
MATERIALS AND METHODOLOGY 
  Patient samples, patient characteristics, and study de-
sign. Peripheral blood samples were obtained from 17 patients 
with RA, at the indicated time points whose B cell regenera-
tion pattern has been published recently [11]. For immunfluo-
rescence staining of Foxp3 peripheral blood samples were 
obtained from seven patients out of 17. Furthermore, in these 
seven patients HLA-G staining was performed and sHLA-G 
was determined in sera of five out of these seven patients. All 
patients met the American College of Rheumatology revised 
criteria for the classification of RA. In all patients, RA was 
refractory to standard treatment with disease-modifying antir-
heumatic drugs, including methotrexate (MTX) and/or tumor 
necrosis factor alpha antagonists (etanercept, adalimumab or 
infliximab). Informed consent was obtained from all patients 
before entering the study, in accordance with the protocol ap-
proved by the ethics committee of the University of 
Wuerzburg. More than 70% (12 of 17) of patients continued to 
receive concomitant MTX. Rituximab was administered as 
follows: patients 1-6 received 4 weekly infusions of rituximab 
at a dose of 375 mg/m2 (range 2.4-3.6 gm); patients 7-17 re-
ceived 2 infusions of 1,000 mg rituximab, 2 weeks apart. Ta-
ble 1 summarizes the characteristics of the patients. Peripheral 
blood was collected from the patients at the time points before 
B cell depletion and 1-3, 4-6, 7-9 and 10-12 months after 
rituximab, respectively. 
 Cell  preparation:  Peripheral blood mononuclear cells 
(PBMCs) were prepared by Ficoll-Paque Plus separation 
(Pharmacia Biotech, Freiburg, Germany). 
 Monoclonal  antibodies: For immunofluorescence stain-
ing, the following cell surface markers were used: CD19 
(phycoerythrin [PE]), CD27 (phycoerythrin [PE]), CD3 
(peridinin chlorophyll protein [PerCP]), CD4 (SK3, 
[PerCP]), CD8 (SK1, [APC]) from Becton Dickinson (Hei-
delberg, Germany); CD4 (fluorescein isothiocyanate 
[FITC]), CD8 (fluorescein isothiocyanate, [FITC]), HLA-DR 
(phycoerythrin [PE]) from Beckmann & Coulter; CD25 (al-
lophycocyanin [APC]), CD56 ([PE]), CD16 ([PE]) from 
Becton Dickinson; anti-human Foxp3 ([PE]) from eBio-
science (San Diego, USA); anti-human HLA-G (MEM-G/9, 
[PE], Exbio, Praha, Czech Republic), rat IgG2a (phyco-
erythrin [PE]) from ACRIS, rat IgG1 ([PE]) and mouse IgG1 
([PE], [PerCP] and [APC]) from Becton Dickinson. 
 Flow  cytometric  analysis: Immunofluorescence staining 
for flow cytometric analysis was performed by incubating 
PBMCs in phosphate buffered saline (PBS) with 10 l of 
monoclonal antibodies for 20 minutes on ice. In each tube, 
1x10
6 cells were suspended. The cells were then washed in 
PBS. Immunfluorescence staining for Foxp3 was performed 
using a commercially available kit from eBioscience (San 
Diego, USA). Four-color staining was performed and fol-
lowed by analysis using the FACSCalibur system (Becton 
Dickinson, San Jose, CA). T and B cells were identified by 
forward versus side scatter (FSC/SSC) gating on viable lym-
phocytes in combination with gating on CD19+ and CD3+ 
cells, respectively. A total of minimum 5,000 events were 
collected for each analysis. The frequency of cell populations 
was calculated using CellQuest software (Becton Dickin-
son). The total numbers of cells were calculated per millilitre 
of blood, based on the frequencies of these cells among lym-
phocytes and the white blood cell count. 
Table 1.  Characteristics of the Patients 
 
Characteristic   Baseline   6 months   12 months 
Age, mean (range) years   48 (28-77)     
Female sex, %   88     
Disease duration, mean (range) years   11.4 (1-28)     
Receiving MTX, %   70.6     
RF positivity, %   88     
DAS28 score, mean (range)   6.1 (3.6-7.8)   4.1 (3.0-6.9)   4.9 (2.4-7.7) 
RF, mean (range) IU/ml   292.7 (17-1,180)   110.5 (12-341)   155.8 (12-617) 
ESR, mean (range) mm/hour   28 (12-38)   15 (7-33)   21 (8-46) 
CRP, mean (range) mg/dl   3.93 (0.6-10.4)  0.79 (0.03-2.24)   1.6 (0.09-5.9) 
  Before therapy  6-8 months  12-16 months 
CD19
+ B cells/μl, mean (range)  77 (43-335)  16 (0-28)  92 (11-132) 
MTX = methotrexate; RF = rheumatoid factor; DAS28 = Disease Activity Score in 28 joints; ESR = erythrocyte sedimentation rate; CRP = C-reactive protein; CD19
+ B cells/μl in 
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  For the analysis of HLA-G positive T cells gates were set 
on lymphocytes according to their characteristic properties in 
the FSC/SSC. Additional gates were set on FSC/CD4 or 
FSC/CD8 dot plots to identify the desired subsets. HLA-G 
expression was assessed in comparison to the respective iso-
type control staining. Due to the low frequency of HLA-G+ 
T cells at least 75.000 events in the lymphocyte gate were 
collected for each analysis. 
 Soluble  HLA-G: To quantify soluble HLA-G (sHLA-G) 
in serum we used a commercially available ELISA Kit (Ex-
bio, Praha, Czech Republic) with a lower limit of detection 
of 0.5 to 1 ng/millilitre according to the manufacturer's pro-
tocol. Serum samples were diluted 1 : 3 in PBS and ELISA 
was performed according to the manufacturer’s instructions. 
All samples were run in duplicates. Cell culture supernatant 
of HLA-G5 transfected HeLA cells (kindly provided by E. 
Weiss, Munich) was used as an internal standard. 
 Statistical  analysis: Statistical analysis was performed 
using an unpaired 2-tailed t-test with bonferroni correction. 
Values are expressed as the mean ± SEM and were calcu-
lated using Excel software and SPSS - software (Statistical 
Product and Service Solutions; SPSS Inc., Chicago, USA). P 
values less than 0.05 were considered significant. 
RESULTS 
B-Cell Compartment 
  After treatment with rituximab all patients showed a de-
pletion of CD19+ B lymphocytes (to < 0.1%) in peripheral 
blood. Peripheral B cell depletion lasted 6 to 9 months after 
Rituximab (mean ± SEM 7.6 ± 0,6 months) [11]. The abso-
lute numbers of CD19+ B lymphocytes returned to baseline 
levels 12 months after therapy (Table 1). Only 1 patient did 
not recover normal B cell numbers, and in that patient the 
levels remained reduced at 11.2 cells/μl. The numerically 
low B cell levels were not accompanied by a special clinical 
course or a different B cell regeneration pattern. 
  B cell depletion was accompanied by a significant clinical 
improvement regarding disease activity like decrease in tender 
and swollen joint count, CRP or ESR (data not shown). 
T-Cell Compartment 
  The absolute number of CD3 positive lymphocytes 
showed no significant changes during the time of B cell de-
pletion and during the regeneration phase up to 1 year after 
B cell depletion compared to before therapy (Table 2). The 
absolute numbers for CD4+ and CD8+ cells showed no sig-
nificant changes either. Nevertheless we observed some 
changes in the composition of the peripheral lymphocyte 
pool. The relative frequency of CD3+ cells was significantly 
increased within 1-12 months after Rituximab (p < 0.05). 
This was related to a statistically significant increase of 
CD4+ T cells. CD8+ T cells did neither show significant 
changes in the absolute numbers nor in the relative fre-
quency. For additional subtypes of T cells neither the relative 
frequency nor the absolute cell number changed significantly 
compared to the timepoint before therapy. This was found 
for CD3+HLA-DR+, CD3+CD16+ and/or 56+, CD3-CD16+ 
and/or 56+, CD8+CD25+, CD8+HLA-DR+, CD4+HLA-
DR+ and CD3++ (data not shown). 
CD4+CD25+ Compartment and Foxp3 
  Since regulatory T cells are thought to be more important 
for the pathophysiology of RA, we studied the CD4+CD25+ 
compartment more in detail. We did not observe any signifi-
cant increase or decrease in the absolute numbers or the rela-
tive frequency of CD4+CD25+ cells (Table 2). In particular, 
also the percentage and absolute cell count for regulatory T 
cells defined as CD4+CD25++ T-cells remained constant 
over the period under review and did not show any statisti-
cally significant changes compared to the timepoint before 
administration of rituximab. 
  Next we studied Fox P3 positive CD4+ T cells. Both, the 
absolute number and the relative frequency of Fox P3 posi-
tive T-cells did not change statistically significant over the 
period under review (Fig. 1). 
HLA-G 
  HLA-G defines a novel subset of regulatory T cells. 
Therefore we studied the numbers of CD4+ and CD8+ HLA-
G+ cells under rituximab treatment. Before initiating rituxi-
Table 2.  Time Course of T-Cell Subsets After B-Cell Depletion with Rituximab Compared to Baseline 
 
% Before  Therapy  1-3  4-6  7-9  10-12 
CD3+  66 ± 10 %  74 ± 11 %*  73 ± 12 %*  73 ± 8 %*  73 ± 8 %* 
CD4+  47 ± 11 %  55 ± 10 %*  51 ± 9 %*  51 ± 10 %*  52 ± 9 %* 
CD8+  26 ± 7 %  25 ± 6 %  28 ± 9 %  27 ± 7 %  26 ± 9 % 
CD4+CD25+  23 ± 8 %  24 ± 13 %  22 ± 8 %  20 ± 7 %  20 ± 10 % 
CD3+HLA DR+  6 ± 5 %  6 ± 7 %  6 ± 5 %  5 ± 3 %  5 ± 4 % 
cells/microlitre 
CD3+  867 ± 537  951 ± 419  923 ± 404  996 ± 584  951 ± 624 
CD4+  630 ± 417  720 ± 299  642 ± 270  718 ± 474  689 ± 475 
CD8+  318 ± 176  304 ± 126  348 ± 161  350 ± 154  324 ± 215 
CD4+CD25+  314 ±196  298 ± 209  265 ± 121  248 ± 108  266 ± 232 
CD3+HLA DR+  69 ± 63  49 ± 25  75 ± 82  59 ± 30  61 ± 68 
Relative frequency within lymphocytes and absolute numbers; mean ± SEM, *p<0.05. 84    The Open Rheumatology Journal, 2008, Volume 2  Feuchtenberger et al. 
mab an average of 0.95% of CD4+ T cells in the peripheral 
blood of RA patients expressed HLA-G (range 0.6% to 
1.7%, n=7). Analysis of HLA-G expression on CD8 revealed 
an average of 1.56 % HLA-G positive CD8+ T cells in RA 
patients (range 0.9% to 3.6%, n= 7). Although the frequency 
of CD4+HLA-G+ and CD8+HLA-G+ varied in between the 
different time points in single patients we could not find a 
significant change for these subpopulations (Fig. 2). The 
absolute cell counts did not show significant changes neither 
for CD4+HLA-G+ nor CD8+HLA-G+ (data not shown). 
sHLA-G 
  Serum levels of sHLA-G were previously found to be 
decreased in RA patients and have been linked to disease 
activity [12]. However, we did not observe a consistent sig-
nificant change in soluble HLA-G as measured by ELISA in 
 
Fig. (1). Time course of CD4+CD25++ and Foxp3 positive T cells (relative frequency within lymphocytes, Foxp3 within CD4+ lympho-
cytes) and absolute numbers after B-cell depletion with rituximab compared to baseline. (mean ± SEM). 
0%
2%
4%
6%
8%
10%
12%
before
therapy
1-3 4-6 7-9 10-12
months
CD4+CD25++
Foxp3
0
20
40
60
80
100
120
before
therapy
1-3 4-6 7-9 10-12
months
c
e
l
l
s
/
m
i
c
r
o
l
i
t
r
e
CD4+CD25++
Foxp3Regulatory T Cells After Rituximab  The Open Rheumatology Journal, 2008, Volume 2    85 
the sera of five patients under rituximab treatment during the 
first year of follow-up (Fig. 3). 
DISCUSSION 
  Both, B and T cells have been shown to be of crucial 
importance in the pathogenesis of autoimmune disorders e.g. 
RA [2, 5, 25]. B cell depletion by rituximab has been ap-
proved for treatment of severe RA refractory to conventional 
DMARDs including TNFalpha inhibitors in combination 
with methotrexate underlining the key function of B cells in 
the pathogenesis in RA [3, 4, 7, 9, 26-28]. Undoubtedly there 
is a linkage between the B and T cell compartment under 
Fig. (2). Mean frequencies of CD4+HLA-G+ and CD8+HLA-G+ as percentages of CD4+ or CD8+ respectively at different time points dur-
ing the first year follow up after initiation of rituximab treatment. (mean ± SEM, n=7). 
 
Fig. (3). Serum levels of sHLA-G during the first year of follow-up after initiation of rituximab therapy as measured by ELISA. (n=5). 
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both physiological and pathological conditions. B cells e.g. 
support the activation of T cells by expressing costimulatory 
molecules such as CD80/86 and CD40 or by the secretion of 
cytokines. Furthermore they function as antigen presenting 
cells and have essential effects on other cells required for the 
development of tertiary lymphoid tissues [24]. Rituximab 
treatment causes a profound peripheral B cell depletion 
which can be observed usually for about 6 months. In addi-
tion it causes dramatic changes in the homeostasis of B cell 
subsets which can be observed for more than a year after 
rituximab treatment [10, 11, 27, 29-31]. 
  There is also evidence for a disturbed T cell homoeosta-
sis within autoimmune diseases, in particular, a disturbance 
of T cells with immunosuppressive and regulatory function 
[12]. Several subsets of T cells with suppressive and regula-
tory functions have been described within the last years. To 
date, only 2 populations of “natural” regulatory T cell popu-
lations can be identified in peripheral blood. 1) the popula-
tion of CD4+CD25++ coexpressing Foxp3 and 2) the re-
cently identified HLA-G-expressing CD4 or CD8 Tregs. 
 Valencia  et al. demonstrated differences regarding the 
expression of Foxp3 in patients with SLE [32]. In rheuma-
toid arthritis, Mottonen et al. studied the characteristics of 
CD4+CD25+ T cells in peripheral blood (PB) and synovial 
fluid (SF) compared to normal controls [23]. They found an 
increased frequency of CD4+ cells T cells expressing CD25 
in SF compared to PB from patients with RA. However, no 
significant difference was observed in the numbers of 
CD4+CD25+ T cells in PB from patients and controls. 
  There is evidence that CD4+CD25++Foxp3+ T regs are 
modulated by anti-TNF therapies [33]. CD4+CD25++ Tregs 
isolated from patients with active rheumatoid arthritis (RA) 
expressed reduced levels of Foxp3 mRNA and protein which 
was ameliorated by inhibition of TNFalpha with infliximab 
[34]. In another study, treatment with infliximab also re-
stored the capacity of regulatory T cells to inhibit cytokine 
production and to induce a suppressive phenotype on 
CD4+CD25- T cells [35]. Furthermore, anti-TNFalpha 
treatment led to a significant rise in the number of peripheral 
blood regulatory T cells in RA patients responding to this 
treatment. These data so far suggest that particularly regula-
tory T cells are of importance also for RA, which can be 
influenced to a certain extent by antiinflammatory treatment. 
  Only little is known about the influence of rituximab me-
diated B-cell depletion on the T-cell compartment and in 
particular on regulatory T-cells. 
 Leandro  et al. could not find significant changes in the 
frequency and absolute number of T cells (CD3+) and NK 
cells (CD3-CD56+) at 1 month and 3 months after rituximab 
in RA. In addition, no significant differences were detected 
in the different subpopulations of T cells like CD4+, CD8+ 
and CD4+ T cells expressing CD25 [10]. Since the clinical 
response to rituximab is somewhat delayed and not yet fully 
developed at 3 months after rituximab and B cell homeosta-
sis is disturbed for more than a year, changes in the T cell 
compartment may also evolve later than three months after 
Rituximab. Therefore we extended these data by analysing T 
cell subpopulation over a period of one year. Both, the rela-
tive frequency and also the absolute number of 
CD4+CD25++ T cells in our population remained constant 
without any significant changes. Despite the fact that we saw 
a significant increase in the relative frequency of CD3+ cells 
and in the CD4+ subset within 1-12 months after Rituximab 
(p < 0.05), the absolute numbers of CD3+ and CD4+ T cells 
as well as CD3+HLA-DR+, CD3+CD16/56+, CD8+CD25+, 
CD8+HLA-DR+, CD4+HLA-DR+ and CD3++ and of NK 
cells (CD3-CD56+) were not significantly altered. This can 
be explained by the lack or reduced levels of B-cells during 
period under review, respectively. Due to extensive pre-
treatment before Rituximab investigated patients in our study 
tended to have low lymphocyte counts. As a consequence 
absolute numbers of T cells were generally low. 
  Of particular interest was the analysis of the Treg com-
partment. In the study by Leandro the frequency of 
CD4+CD25++ T cells decreased 1 month after treatment 
significantly (p < 0.05), but the total numbers did not, and no 
significant differences were found at 3 months. In our popu-
lation we could not find a decrease in the frequency of 
CD4+CD25++ within 3 months after Rituximab. However, 
we did not specifically look within the first 4 weeks after 
rituximab since we thought this period to be confounded by 
the i.v prednisolone used during antibody infusions. The 
relative frequency and also the absolute number of 
CD4+CD25++ T cells remained constant without any sig-
nificant changes up to one year after initiating B cell deple-
tion. Also the numbers of Foxp3+CD4+ T cells remained 
constant under rituximab treatment. In lupus nephritis Sfika-
kis et al. could show increased Foxp3 mRNA after B cell 
depletion by Rituximab in peripheral blood of 7 patients 
[36]. During follow-up, increased Foxp3 mRNA persisted in 
those patients in clinical remission, while in those patients 
with active disease subsequent decreases were noted. It is not 
clear whether the different techniques for defining Foxp3+ 
Treg or the different pathophysiology between RA and lupus 
accounts for these differences. 
  An interesting new subset of regulatory T cells which 
does not share the CD25++ Foxp3 phenotype are the HLA-G 
expressing Treg. HLA-G expressing T cells represent a 
novel subset of natural occurring regulatory T cells, that effi-
ciently inhibit autologous T cell proliferation via a yet to be 
defined cell-contact independent mechanism. HLA-G posi-
tive T cells can be found at low percentages in the peripheral 
blood of healthy volunteers and the presence of HLA-G+ T 
cells at sites of inflammation due to infections or autoreac-
tivity like neuroinflammatory disorders (e.g. multiple sclero-
sis, vasculitis, encephalitis or myositis) suggests an impor-
tant function of these cells in modulating inflammatory re-
sponses in vivo [37, 38]. Similar to membrane bound HLA-G 
on T cells Verbruggen et al. were able to demonstrate that 
soluble HLA-G was lower in RA but positively correlated 
with parameters of RA disease activity [19]. However, we 
did not observe a consistent significant change in soluble 
HLA-G as measured by ELISA in the sera of five patients 
under rituximab treatment. 
  From our data, there seems to be no evidence for any 
numerical influence of CD20 mediated B cell depletion on 
the amounts and frequency of regulatory T cells in peripheral 
blood in RA. For future studies it will be relevant to extend 
the analysis of Tregs to their function, since the available 
data give no indication whether B cell depletion is able to 
restore defective regulatory T cell activity. Results regarding Regulatory T Cells After Rituximab  The Open Rheumatology Journal, 2008, Volume 2    87 
T cell subsets after B cell depletion via Rituximab may also 
vary depending on the underlying disease. To address this, 
there is an obvious need for further studies on the impact of 
therapeutic B cell depletion on T cell subsets. 
CONCLUSION 
  Our data for patients with RA indicate that absolute T 
cell counts do not change significantly after rituximab com-
pared to the time before therapy for all studied populations in 
peripheral blood. In particular, the frequency and the abso-
lute number of regulatory T cells defined as T cells charac-
terized by CD4+/CD25++, Fox P3 or HLA-G expression 
were numerically stable during transient B-cell depletion 
using anti-CD20 antibodies up to 12 months in the peripheral 
blood. 
ABBREVIATIONS 
RA =  Rheumatoid  arthritis 
SLE =  Systemic  lupus  erythematosus 
CD  =  Cluster of differentiation 
TNFalpha   =  Tumor necrosis factor alpha 
DMARDs   =  Disease modifying anti-rheumatic drugs 
MTX =  Methotrexate 
PB =  Peripheral  blood 
Treg =  Regulatory  T  cells 
APC  =  Antigen presenting cells 
PBMCs   =  Peripheral blood mononuclear cells 
DAS28   =  Disease Activity Score in 28 joints 
ESR   =  Erythrocyte sedimentation rate; 
CRP =  C-reactive  protein 
SF =  Synovial  fluid 
NK cells  =  Natural killer cells 
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